Abstract
In a phase 3 randomised study, Hartmut Goldschmidt and colleagues1 from the German-Speaking Myeloma Multicenter Group (GMMG) explored the addition of an anti-CD38 monoclonal antibody isatuximab to standard induction therapy with lenalidomide, bortezomib, and dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma. The primary endpoint of part 1 of this study was minimal residual disease negativity, as assessed by next-generation flow cytometry with a sensitivity cutoff of 1 × 105 cells after induction therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
